Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb7195
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs XmAb 7195 (Primary) ; XmAb 7195 (Primary)
- Indications Allergic asthma; Hypersensitivity
- Focus Pharmacokinetics
- Sponsors Xencor
- 09 May 2017 According to a Xencor media release, top-line data is expected in 2017.
- 01 May 2017 Status changed from active, no longer recruiting to completed.
- 23 Mar 2017 Planned End Date changed from 1 Oct 2017 to 1 Sep 2017.